{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:20:53Z","timestamp":1770682853665,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s10120-024-01548-9","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T13:02:36Z","timestamp":1724763756000},"page":"1229-1241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preclinical toxicological assessment of amido-bridged nucleic acid-modified antisense oligonucleotides targeting synaptotagmin XIII for intra-abdominal treatment of peritoneal metastasis of gastric cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-3819","authenticated-orcid":false,"given":"Mitsuro","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuuya","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Obika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"1548_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","volume":"23","author":"TE Nakajima","year":"2020","unstructured":"Nakajima TE, Yamaguchi K, Boku N, Hyodo I, Mizusawa J, Hara H, et al. Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G). Gastric Cancer. 2020;23:677\u201388.","journal-title":"Gastric Cancer"},{"key":"1548_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"1548_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347.","journal-title":"Lancet Oncol"},{"key":"1548_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/SLA.0000000000002096","volume":"267","author":"M Kanda","year":"2018","unstructured":"Kanda M, Shimizu D, Tanaka H, Tanaka C, Kobayashi D, Hayashi M, et al. Significance of SYT8 for the detection, prediction, and treatment of peritoneal metastasis from gastric cancer. Ann Surg. 2018;267:495\u2013503.","journal-title":"Ann Surg"},{"key":"1548_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000502484","volume":"98","author":"D Kobayashi","year":"2020","unstructured":"Kobayashi D, Ishigami H, Kanda M, Tanaka C, Yamaguchi H, Kitayama J, et al. Phase I study of intraperitoneal administration of paclitaxel combined with S-1 plus cisplatin for gastric cancer with peritoneal metastasis. Oncology. 2020;98:48\u201352.","journal-title":"Oncology"},{"key":"1548_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922\u20139.","journal-title":"J Clin Oncol"},{"key":"1548_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1245\/s10434-023-14240-6","volume":"31","author":"D Kobayashi","year":"2024","unstructured":"Kobayashi D, Kodera Y, Fukushima R, Morita M, Fushida S, Yamashita N, et al. Phase II study of intraperitoneal administration of paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2024;31:735\u201343.","journal-title":"Ann Surg Oncol"},{"key":"1548_CR8","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/bjs.10876","volume":"105","author":"M Kanda","year":"2018","unstructured":"Kanda M, Shimizu D, Tanaka H, Tanaka C, Kobayashi D, Hayashi M, et al. Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer. Br J Surg. 2018;105:1349\u201358.","journal-title":"Br J Surg"},{"key":"1548_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.omtn.2020.10.001","volume":"22","author":"M Kanda","year":"2020","unstructured":"Kanda M, Kasahara Y, Shimizu D, Miwa T, Umeda S, Sawaki K, et al. Amido-bridged nucleic acid-modified antisense oligonucleotides targeting SYT13 to treat peritoneal metastasis of gastric cancer. Mol Ther Nucleic Acids. 2020;22:791\u2013802.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1548_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/10408363.2019.1653821","volume":"56","author":"F Moosavi","year":"2019","unstructured":"Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF\/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci. 2019;56:533\u201366.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1548_CR11","first-page":"995","volume":"13","author":"EJ Jung","year":"2020","unstructured":"Jung EJ, Suh JH, Kim WH, Kim HS. Clinical significance of PI3K\/Akt\/mTOR signaling in gastric carcinoma. Int J Clin Exp Pathol. 2020;13:995\u20131007.","journal-title":"Int J Clin Exp Pathol"},{"key":"1548_CR12","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/cbic.201200506","volume":"13","author":"A Yahara","year":"2012","unstructured":"Yahara A, Shrestha AR, Yamamoto T, Hari Y, Osawa T, Yamaguchi M, et al. Amido-bridged nucleic acids (AmNAs): synthesis, duplex stability, nuclease resistance, and in vitro antisense potency. ChemBioChem. 2012;13:2513\u20136.","journal-title":"ChemBioChem"},{"key":"1548_CR13","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1039\/C5OB00242G","volume":"13","author":"T Yamamoto","year":"2015","unstructured":"Yamamoto T, Yahara A, Waki R, Yasuhara H, Wada F, Harada-Shiba M, et al. Amido-bridged nucleic acids with small hydrophobic residues enhance hepatic tropism of antisense oligonucleotides in vivo. Org Biomol Chem. 2015;13:3757\u201365.","journal-title":"Org Biomol Chem"},{"key":"1548_CR14","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1093\/nar\/gkv626","volume":"43","author":"S Hori","year":"2015","unstructured":"Hori S, Yamamoto T, Waki R, Wada S, Wada F, Noda M, et al. Ca2+ enrichment in culture medium potentiates effect of oligonucleotides. Nucleic Acids Res. 2015;43:e128.","journal-title":"Nucleic Acids Res"},{"key":"1548_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-020-01251-0","volume":"19","author":"M Kanda","year":"2020","unstructured":"Kanda M, Shimizu D, Sawaki K, Nakamura S, Umeda S, Miwa T, et al. Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer. Mol Cancer. 2020;19:131.","journal-title":"Mol Cancer"},{"key":"1548_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0896-6273(02)00834-6","volume":"35","author":"M Katsuno","year":"2002","unstructured":"Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35:843\u201354.","journal-title":"Neuron"},{"key":"1548_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1006\/mcpr.2000.0296","volume":"14","author":"P Zhang","year":"2000","unstructured":"Zhang P, Gebhart CJ, Burden D, Duhamel GE. Improved diagnosis of porcine proliferative enteropathy caused by Lawsonia intracellularis using polymerase chain reaction-enzyme-linked oligosorbent assay (PCR-ELOSA). Mol Cell Probes. 2000;14:101\u20138.","journal-title":"Mol Cell Probes"},{"key":"1548_CR18","doi-asserted-by":"publisher","first-page":"9204","DOI":"10.1021\/ac401941x","volume":"85","author":"M Lereau","year":"2013","unstructured":"Lereau M, Fournier-Wirth C, Mayen J, Farre C, Meyer A, Dugas V, et al. Development of innovative and versatile polythiol probes for use on ELOSA or electrochemical biosensors: application in hepatitis C virus genotyping. Anal Chem. 2013;85:9204\u201312.","journal-title":"Anal Chem"},{"key":"1548_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm"},{"key":"1548_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1078\/0171-9335-00133","volume":"80","author":"C von Poser","year":"2001","unstructured":"von Poser C, Sudhof TC. Synaptotagmin 13: structure and expression of a novel synaptotagmin. Eur J Cell Biol. 2001;80:41\u20137.","journal-title":"Eur J Cell Biol"},{"key":"1548_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00401-020-02133-x","volume":"139","author":"M Nizzardo","year":"2020","unstructured":"Nizzardo M, Taiana M, Rizzo F, Aguila Benitez J, Nijssen J, Allodi I, et al. Synaptotagmin 13 is neuroprotective across motor neuron diseases. Acta Neuropathol. 2020;139:837\u201353.","journal-title":"Acta Neuropathol"},{"key":"1548_CR22","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s12094-022-03058-5","volume":"25","author":"YD Zhang","year":"2023","unstructured":"Zhang YD, Zhong R, Liu JQ, Sun ZX, Wang T, Liu JT. Role of synaptotagmin 13 (SYT13) in promoting breast cancer and signaling pathways. Clin Transl Oncol. 2023;25:1629\u201340.","journal-title":"Clin Transl Oncol"},{"key":"1548_CR23","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1038\/s41467-022-31862-8","volume":"13","author":"M Bakhti","year":"2022","unstructured":"Bakhti M, Bastidas-Ponce A, Tritschler S, Czarnecki O, Tarquis-Medina M, Nedvedova E, et al. Synaptotagmin-13 orchestrates pancreatic endocrine cell egression and islet morphogenesis. Nat Commun. 2022;13:4540.","journal-title":"Nat Commun"},{"key":"1548_CR24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.omtn.2021.10.008","volume":"26","author":"F Wada","year":"2021","unstructured":"Wada F, Yamamoto T, Kobayashi T, Tachibana K, Ito KR, Hamasaki M, et al. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides. Mol Ther Nucleic Acids. 2021;26:957\u201369.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1548_CR25","doi-asserted-by":"publisher","first-page":"7567","DOI":"10.1038\/s41598-019-43772-9","volume":"9","author":"T Uehara","year":"2019","unstructured":"Uehara T, Choong CJ, Nakamori M, Hayakawa H, Nishiyama K, Kasahara Y, et al. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting \u03b1-synuclein as a novel therapy for Parkinson\u2019s disease. Sci Rep. 2019;9:7567.","journal-title":"Sci Rep"},{"key":"1548_CR26","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.1038\/s41598-019-43100-1","volume":"9","author":"M Shimojo","year":"2019","unstructured":"Shimojo M, Kasahara Y, Inoue M, Tsunoda SI, Shudo Y, Kurata T, et al. A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer. Sci Rep. 2019;9:7618.","journal-title":"Sci Rep"},{"key":"1548_CR27","doi-asserted-by":"publisher","first-page":"106900","DOI":"10.1016\/j.vascn.2020.106900","volume":"105","author":"DJ Leishman","year":"2020","unstructured":"Leishman DJ, Abernathy MM, Wang EB. Revisiting the hERG safety margin after 20 years of routine hERG screening. J Pharmacol Toxicol Methods. 2020;105:106900.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"1548_CR28","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1080\/07391102.2021.1875883","volume":"40","author":"S Koulgi","year":"2022","unstructured":"Koulgi S, Jani V, Nair V, Saini JS, Phukan S, Sonavane U, et al. Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity. J Biomol Struct Dyn. 2022;40:5996\u20136012.","journal-title":"J Biomol Struct Dyn"},{"key":"1548_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","volume":"43","author":"KS Frazier","year":"2015","unstructured":"Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective. Toxicol Pathol. 2015;43:78\u201389.","journal-title":"Toxicol Pathol"},{"key":"1548_CR30","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/01926233221100414","volume":"50","author":"KS Frazier","year":"2022","unstructured":"Frazier KS. Kidney effects by alternative classes of medicines in patients and relationship to effects in nonclinical toxicity studies. Toxicol Pathol. 2022;50:408\u201314.","journal-title":"Toxicol Pathol"},{"key":"1548_CR31","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.3390\/pharmaceutics14122647","volume":"14","author":"C Terada","year":"2022","unstructured":"Terada C, Kawamoto S, Yamayoshi A, Yamamoto T. Chemistry of therapeutic oligonucleotides that drives interactions with biomolecules. Pharmaceutics. 2022;14:2647.","journal-title":"Pharmaceutics"},{"key":"1548_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000209277","volume":"76","author":"H Ishigami","year":"2009","unstructured":"Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009;76:311\u20134.","journal-title":"Oncology"},{"key":"1548_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/annonc\/mdp260","volume":"21","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67\u201370.","journal-title":"Ann Oncol"},{"key":"1548_CR34","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, et al. Phase I trial of intraperitoneal taxol: a gynecoloic oncology group study. J Clin Oncol. 1992;10:1485\u201391.","journal-title":"J Clin Oncol"},{"key":"1548_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000323272","volume":"79","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Yamaguchi H, Yamashita H, Emoto S, et al. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis. Oncology. 2010;79:269\u201372.","journal-title":"Oncology"},{"key":"1548_CR36","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s10120-019-00967-3","volume":"22","author":"K Nakanishi","year":"2019","unstructured":"Nakanishi K, Kanda M, Umeda S, Tanaka C, Kobayashi D, Hayashi M, et al. The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer. Gastric Cancer. 2019;22:1143\u201352.","journal-title":"Gastric Cancer"},{"key":"1548_CR37","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/jcb.29224","volume":"121","author":"L Zhang","year":"2020","unstructured":"Zhang L, Fan B, Zheng Y, Lou Y, Cui Y, Wang K, et al. Identification SYT13 as a novel biomarker in lung adenocarcinoma. J Cell Biochem. 2020;121:963\u201373.","journal-title":"J Cell Biochem"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-024-01548-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-024-01548-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-024-01548-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:11:35Z","timestamp":1764267095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-024-01548-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1007\/s10120-024-01548-9","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Animal Research Committee of Nagoya University approved experiments employing\n                      Syt13\n                      -deficient mice (Protocol review no. 2175008). All pharmacokinetics and toxicity tests complied with the principles of the \"Guide for Care and Use of Laboratory Animals.\u201d. These analyses were conducted at Ina Research Inc. (Ina, Japan), which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC 001107).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}